President and Chief Executive Officer
Mr. Turgeon brings more than 30 years of experience in the pharmaceutical industry, including various executive leadership roles at Amgen Inc. He had served as Spectrum’s President and Chief Operating Officer since April 2014, and had previously served as the Company’s Senior Vice President and Chief Commercial Officer from October 2012 to April 2014. Prior to joining Spectrum, Mr. Turgeon spent 22 years at Amgen Inc. as Vice President of Sales. At Amgen he built and led the sales organization across multiple areas, including oncology, inflammation and bone health. Mr. Turgeon was responsible for launching most of the drugs and their dramatic growth at Amgen. He brings depth of experience in the oncology marketplace.
Mr. Turgeon holds a B.S. from Jacksonville University where he studied microbiology and economics.
Chief Operating Officer
Mr. Riga brings over 20 years of pharmaceutical sales and management experience in various positions at Wyeth Ayerst, Eli Lilly, Amgen and Dendreon. His experience spans sales, Six Sigma, marketing, manufacturing, and corporate accounts.
He had served as Spectrum’s Executive Vice President , Chief Commercial Officer and Head of Business Development since June 2017, and previously served as Spectrum’s Senior Vice President and Chief Commercial Officer from August 2014 to June 2017, and Vice President, Corporate Accounts from July 2013 to August 2014.
Mr. Riga holds a B.S. from St. Lawrence University where he studied Biology and Chemistry.
Executive Vice President, Chief Financial Officer and Principal Accounting Officer
Mr. Gustafson has more than 20 years of diverse experience in corporate finance, with 15 years in senior management roles leading the finance departments of multi-faceted, dynamic and growth oriented biopharmaceutical industry organizations.
Prior to joining Spectrum, Mr. Gustafson served as Vice President and Chief Financial Officer at Halozyme Therapeutics, Inc., a publicly-traded biopharmaceutical company, where he managed several successful financings and established a three year mid-range planning process to align resource allocations to long term strategic goals. Before Halozyme, Mr. Gustafson worked at Amgen for over 18 years most recently as Vice President, Finance, with responsibility for financial planning and cost accounting for worldwide manufacturing covering seven manufacturing sites. During his tenure at Amgen, Mr. Gustafson also served as CFO of Amgen International and resided in Zug, Switzerland.
Mr. Gustafson holds a Bachelors of Arts degree in Accounting from North Park University in Chicago and a Masters in Business Administration from University of California, Los Angeles.
Senior Vice President, Pharmaceutical Operations
Pramod Gupta is responsible for product development, and commercial manufacturing and supply chain, of Spectrum products. His product development responsibilities include chemical development, formulation development, analytical development, scale-up/manufacturing, stability studies, clinical supplies and intellectual property. His supply chain responsibilities include commercial product inventory management, product manufacturing and shipment, and contracts management.
Pramod has over 25 years’ experience in the pharmaceutical industry including Abbott, Baxter and Bausch & Lomb, where he held positions of increasing responsibilities. He has been part of over 12 approved NDAs and over 35 product launches globally. Pramod holds PhD in Pharmaceutical Sciences, has published more than 50 papers and 2 scientific books, and holds over 12 granted patents. He has also served as an expert committee member for the United States Pharmacopoeia.
Senior Vice President, Clinical Development
Dr. Yang joins Spectrum from Inovio Pharmaceuticals where he was Vice President, Clinical Development Oncology for Inovio's entire Oncology Therapeutic Area. He led Inovio's Clinical Development for all oncology immunotherapies and cancer vaccines, as well as all collaborative activities with external organizations. Prior to Inovio, he was Director of Medical Affairs and Clinical Development at Janssen, Novartis Oncology and Merck & Co.Dr. Yang, who earned his M.D. at Beijing Medical University, was a fellow at Emory University's Winship Cancer Institute, University of Pennsylvania and the Wistar Institute in Philadelphia. Before transitioning to the pharmaceutical industry, he was associate professor at the University of Virginia Medical Center in Charlottesville, VA.
Vice President, Sales
Vice President, Corporate and Business Development